Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year
- Anette Jørgensen1,
- Kristian Stengaard-Pedersen1,
- Ole Simonsen2,
- Mogens Pfeiffer-Jensen1,
- Christian Eriksen2,
- Henning Bliddal3,
- Niels Wisbech Pedersen4,
- Søren Bødtker5,
- Kim Hørslev-Petersen6,
- Lennart Ørtoft Snerum7,
- Niels Egund8,
- Helle Frimer-Larsen9
- 1Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
- 2Orthopaedic Division, North Denmark Region, Aalborg Hospital, part of Aarhus University Hospital, Denmark
- 3Clinic of Rheumatology, Parker Institute/Frederiksberg Hospital, Frederiksberg, Denmark
- 4Department of Orthopaedics, Odense University Hospital, Odense, Denmark
- 5Department of Orthopaedics, Herlev University Hospital, Herlev, Denmark
- 6King Christian X’s Hospital for Rheumatic Diseases, Graasten, Denmark
- 7Department of Orthopaedics, Holstebro Hospital, Holstebro, Denmark
- 8Department of Radiology, Aarhus University Hospital, Aarhus, Denmark
- 9Larix ApS, Værløse, Denmark
- Correspondence to Dr Kristian Stengaard-Pedersen, Department of Rheumatology, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark;
- Accepted 3 December 2009
- Published Online First 6 May 2010
Objective To examine the long-term efficacy and safety of five intra-articular injections with hyaluronan in knee osteoarthritis.
Methods A multicentre, randomised, placebo-controlled double-blind study of 337 patients fulfilling the American College of Rheumatology (ACR) criteria for knee osteoarthritis (clinical and laboratory) and with a Lequesne algofunctional index score (LFI) of 10 or greater. Patients received a hyaluronan product (sodium hyaluronate; Hyalgan) (n=167) or saline (n=170) intra-articularly weekly for 5 weeks and were followed up to 1 year. Time to recurrence was the primary efficacy parameter. LFI, pain on walking 50 m based on visual analogue scale (VAS pain 50 m), paracetamol consumption, patients' global assessment, Nottingham health profile, joint effusion and number of responders were secondary efficacy parameters. The efficacy parameters were analysed by intention to treat (ITT) and per protocol (PP). All adverse events (AE) were recorded as safety parameters.
Results Time to recurrence showed no significant treatment effect (ITT analysis, p=0.26). Change from baseline in LFI and VAS pain 50 m for the ITT population showed no treatment effect. Paracetamol consumption, patients' global assessment, responder rates and AE displayed no significant difference between treatment groups, analysed by both ITT and PP. Treatment compliance was 95% in the hyaluronan group and 99% in the placebo group. No safety problems were registered.
Conclusion In patients fulfilling the ACR criteria for osteoarthritis of the knee with moderate to severe disease activity (LFI ≥10), five intra-articular injections of hyaluronan did not improve pain, function, paracetamol consumption or other efficacy parameters 3, 6, 9 and 12 months after the treatment.
Funding This is an investigator-initiated study that was planned and carried out at the Department of Rheumatology, Aarhus University Hospital in collaboration with seven other Danish departments. The study was supported by Nycomed Denmark A/S with blinded hyaluronan/placebo medication free of charge and good clinical practice monitoring.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Scientific Ethical Committee for Århus County.
Provenance and peer review Not commissioned; externally peer reviewed.